Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients

Changes in UCP2 mRNA in T2DM Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01781754

Acronym

Diabetes

Enrollment

Registered

2013-02-01

Start date

2013-01-31

Completion date

2014-01-31

Last updated

2013-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Keywords

Glycemic control, Metabolic control, Oxidative stress, Diabetes

Brief summary

Many patients with Diabetes find difficulties in achieving glycemic control. Hemoglobin A1c(HgBA1c) is used as a marker for glycemic control. UCP2 is affected by high glucose levels, high free fatty acids and high oxidative stress. The investigators intend to learn about the changes in UCP2 along the process of reaching glycemic control.

Interventions

PROCEDUREBlood withdrawal

This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Un balanced diabetic patients.

Exclusion criteria

* No current infection.

Design outcomes

Primary

Measure	Time frame	Description
Levels of gene expression for UCP2 (RQ)	6 months	Checking UCP2 levels compared to HgBA1c

Secondary

Measure	Time frame	Description
Improved metabolic state	6 months	Glycemic control (glucose level and HgA1c), levels of free reactive oxygen species (ROS) and non-esterified fatty acids (NEFAs).

Countries

Israel

Contacts

Primary ContactNachum Vaisman, MD

vaisman@tasmc.health.gov.il972-3-6974807

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026